Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

$323.69 +3.03 (+0.94%)

(As of 11/20/2024 ET)

Bio-Rad Laboratories - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 5 Analyst Ratings

Sell
0

Hold
2

Buy
3

Based on 5 Wall Street analysts who have issued ratings for Bio-Rad Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 2 have given a hold rating, and 3 have given a buy rating for BIO.

Consensus Price Target

$391.80
21.04% Upside

According to the 5 analysts' twelve-month price targets for Bio-Rad Laboratories, the average price target is $391.80. The highest price target for BIO is $469.00, while the lowest price target for BIO is $315.00. The average price target represents a forecasted upside of 21.04% from the current price of $323.69.

Get the Latest News and Ratings for BIO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bio-Rad Laboratories and its competitors.

BIO Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$391.80	$368.20	$362.75	$533.00
Forecasted Upside	21.04% Upside	8.26% Upside	15.18% Upside	72.00% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Get Your Free Gold Guide

BIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bio-Rad Laboratories Stock vs. The Competition

Type	Bio-Rad Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.60	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	21.04% Upside	26,931.54% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent BIO News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/31/2024	Citigroup 3 of 5 stars	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$400.00 ➝ $450.00	+25.63%
10/31/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$446.00 ➝ $469.00	+32.25%
8/27/2024	Wells Fargo & Company 3 of 5 stars	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$340.00	+6.36%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$440.00 ➝ $315.00	+8.09%
5/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$420.00 ➝ $385.00	+38.60%
8/4/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$580.00 ➝ $550.00	+36.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:05 AM ET.

BIO Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Bio-Rad Laboratories is $391.80, with a high forecast of $469.00 and a low forecast of $315.00.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIO shares.
: According to analysts, Bio-Rad Laboratories's stock has a predicted upside of 21.04% based on their 12-month stock forecasts.
: Over the previous 90 days, Bio-Rad Laboratories's stock had 1 upgrade by analysts.
: Bio-Rad Laboratories has been rated by research analysts at Citigroup, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.
: Analysts like Bio-Rad Laboratories less than other "medical" companies. The consensus rating score for Bio-Rad Laboratories is 2.60 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BIO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

This page (NYSE:BIO) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target